PL352106A1 - Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines - Google Patents

Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Info

Publication number
PL352106A1
PL352106A1 PL00352106A PL35210600A PL352106A1 PL 352106 A1 PL352106 A1 PL 352106A1 PL 00352106 A PL00352106 A PL 00352106A PL 35210600 A PL35210600 A PL 35210600A PL 352106 A1 PL352106 A1 PL 352106A1
Authority
PL
Poland
Prior art keywords
antilipemic
carnitines
hmg
combinations
coa reductase
Prior art date
Application number
PL00352106A
Other versions
PL197899B1 (en
Inventor
Arduino Arduini
Alessandro Peschechera
Paolo Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/en
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PL352106A1 publication Critical patent/PL352106A1/en
Publication of PL197899B1 publication Critical patent/PL197899B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL352106A 1999-06-08 2000-06-05 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines PL197899B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
EP99830415A EP1064943B1 (en) 1999-06-30 1999-06-30 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
PCT/EP2000/005091 WO2000074675A1 (en) 1999-06-08 2000-06-05 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Publications (2)

Publication Number Publication Date
PL352106A1 true PL352106A1 (en) 2003-07-28
PL197899B1 PL197899B1 (en) 2008-05-30

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
PL352106A PL197899B1 (en) 1999-06-08 2000-06-05 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Country Status (10)

Country Link
JP (1) JP2003501385A (en)
KR (1) KR100725263B1 (en)
AU (1) AU782188B2 (en)
CA (1) CA2375378C (en)
CZ (1) CZ20014218A3 (en)
HU (1) HUP0201597A3 (en)
MX (1) MXPA01012644A (en)
PL (1) PL197899B1 (en)
SK (1) SK285900B6 (en)
WO (1) WO2000074675A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2124925T3 (en) * 2007-02-27 2018-09-28 Alfasigma S.P.A. Composition useful for the treatment of type 2 diabetes
HUE025394T2 (en) * 2007-03-21 2016-02-29 Sigma Tau Ind Farmaceuti Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
AU2009219050B2 (en) * 2008-02-29 2014-04-24 Biolab Sanus Farmaceutica Ltda. Pharmaceutical composition comprising racetam and carnitine and process for its preparation
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (en) * 1985-11-28 1994-08-31 雪印乳業株式会社 Enteral nutrition
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
IT1293067B1 (en) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY ALTERED LIPID METABOLISM

Also Published As

Publication number Publication date
KR100725263B1 (en) 2007-06-07
KR20020025066A (en) 2002-04-03
WO2000074675A1 (en) 2000-12-14
CZ20014218A3 (en) 2002-04-17
SK285900B6 (en) 2007-10-04
JP2003501385A (en) 2003-01-14
MXPA01012644A (en) 2002-07-22
AU782188B2 (en) 2005-07-07
HUP0201597A2 (en) 2002-09-28
CA2375378C (en) 2009-08-11
SK17152001A3 (en) 2002-03-05
HUP0201597A3 (en) 2003-04-28
CA2375378A1 (en) 2000-12-14
AU5969700A (en) 2000-12-28
PL197899B1 (en) 2008-05-30

Similar Documents

Publication Publication Date Title
PL359820A1 (en) Hmg-coa reductase inhibitors and method
GB9900416D0 (en) Inhibitors
PL356066A1 (en) Caspase inhibitors and uses thereof
AU7989400A (en) Compounds and methods
AU3215500A (en) Compounds and methods
AU5991699A (en) Quinolizinones as integrin inhibitors
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
AU5213300A (en) 2-nh-pyridones and pyrimidones as mrs inhibitors
IL132786A0 (en) Hmg-coa reductase inhibitor preparation process
AU1824201A (en) Polymorphisms in the human HMG-COA reductase gene
AU7126900A (en) Enzyme inhibitors
AU3235100A (en) Prothease inhibitors
GB9924522D0 (en) Enzyme inhibitors
AU6992500A (en) Alphavbeta3 integrin inhibitors
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
PL352106A1 (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
GB0225169D0 (en) Secure and mediated access for e-services
GB2389113B (en) B-secretase inhibitor
AU3595900A (en) Tyrosine alkoxyguanidines as integrin inhibitors
AU7559600A (en) V type and/or x type spla2 inhibitors
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU7127100A (en) Enzyme inhibitors
HK1049666A1 (en) NOVEL INTEGRIN α V β INHIBITORS